Ticker brief
NVS NOVARTIS AG-SPONSORED ADR
Consumer, Non-cyclical · Pharmaceuticals
last close
$159.90
1 day
+3.7%
14 days
+8.7%
mkt cap
$305.1B
signals 14d
14
authors 14d
8
Sentiment — last 14 days
daily mean sentiment, 2026-06-21 → 2026-07-02 · now +0.00 (−1 bearish … +1 bullish)
Who spoke8
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @Quantumup1 | C | -1.95 | 5 | +0.00 |
| @FierceBiotech | A | -0.09 | 2 | +0.15 |
| @bioinvestor24 | A | +1.35 | 2 | +0.00 |
| @BiopharmIQ | B | · | 1 | +0.00 |
| @andrewrocco1 | C | -0.99 | 1 | +0.35 |
| @fwpharma | B | +0.22 | 1 | +0.25 |
| @TheProfInvestor | C | +0.27 | 1 | +0.55 |
| @adamfeuerstein | A | +1.05 | 1 | +0.00 |
Recent signals14of 14 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-07-02 | @Quantumup1 | +0.00 | UBS initiates CRNX Buy-$55, citing pullback and pipeline catalysts. | — | tweet ↗ |
| 2026-06-29 | @adamfeuerstein | +0.00 | Pushes back on M&A speculation around NVS jet by citing CEO Anthropic event. | +1.5% | tweet ↗ |
| 2026-06-29 | @FierceBiotech | +0.20 | Evommune phase 2b trial flop ends challenge to Novartis in hives | +1.5% | tweet ↗ |
| 2026-06-27 | @TheProfInvestor | +0.55 | Bullish healthcare rotation basket with ETFs and names, saying theme is not done. | +2.9% | tweet ↗ |
| 2026-06-26 | @bioinvestor24 | +0.10 | Expects ERAS data and bidding-war leak later this year; says BP may acquire RAS glues soon. | +2.9% | tweet ↗ |
| 2026-06-25 | @bioinvestor24 | -0.10 | Says PFE and competitors misunderstand GIP, making LLY lucky. | +3.1% | tweet ↗ |
| 2026-06-25 | @Quantumup1 | +0.00 | Guggenheim raised TVTX PT to $65 from $56 and reiterated Buy/Best Idea. | +3.1% | tweet ↗ |
| 2026-06-25 | @Quantumup1 | +0.00 | Canaccord reiterated PVLA Buy with $227 target after physician survey. | +3.1% | tweet ↗ |
| 2026-06-25 | @Quantumup1 | +0.00 | Cantor reiterated SPRY Overweight with $30 despite PBM formulary delay. | +3.1% | tweet ↗ |
| 2026-06-24 | @fwpharma | +0.25 | Novartis taps Antares in $1.9B oncology deal. | +4.4% | tweet ↗ |
| 2026-06-24 | @FierceBiotech | +0.10 | Novartis pays $105mn upfront in cancer drug discovery deal worth up to $1.9bn. | +4.4% | tweet ↗ |
| 2026-06-23 | @andrewrocco1 | +0.35 | Frames biotech as a 5-year base breakout across ETFs and names. | +4.3% | tweet ↗ |
| 2026-06-22 | @Quantumup1 | +0.00 | Stifel reiterated CRNX Buy and $83 PT after management discussion. | +7.4% | tweet ↗ |
| 2026-06-21 | @BiopharmIQ | +0.00 | Biotech catalyst watchlist for Phase 2 and Phase 3 readouts in Q2/H1 2026. | +8.7% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.